# Gynecology

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Comments</th>
<th>Type</th>
<th>Investigator</th>
<th>Contact</th>
</tr>
</thead>
</table>
| NRG GY018  | A Phase III Randomized, Placebo-controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measureable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer | Treatment    | CRCWM        | (616) 391-1230  
www.crcwm.org |
| NRG GY006  | Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer; Phase II; Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine | Treatment    | CRCWM        | (616) 391-1230  
www.crcwm.org |
| NRG GY005  | PLATINUM-RESISTANT OR -REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY/Recurrent, Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy | Treatment    | CRCWM        | (616) 391-1230  
www.crcwm.org |
| NRG GY009  | A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer | Treatment    | CRCWM        | (616) 391-1230  
www.crcwm.org |